Log in
ASX:RCE

Recce Pharmaceuticals Ltd (RCE.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.48
MA: A$0.48
A$0.48
52-Week Range N/A
Volume630,087 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotics. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 8075 4585
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.12 million
Book ValueA$0.02 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive RCE News and Ratings via Email

Sign-up to receive the latest news and ratings for RCE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Recce Pharmaceuticals Ltd (RCE.AX) (ASX:RCE) Frequently Asked Questions

What stocks does MarketBeat like better than Recce Pharmaceuticals Ltd (RCE.AX)?

Wall Street analysts have given Recce Pharmaceuticals Ltd (RCE.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Recce Pharmaceuticals Ltd (RCE.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Recce Pharmaceuticals Ltd (RCE.AX)'s earnings last quarter?

Recce Pharmaceuticals Ltd (RCE.AX) (ASX:RCE) released its earnings results on Wednesday, February, 27th. The company reported ($0.01) EPS for the quarter.
View Recce Pharmaceuticals Ltd (RCE.AX)'s earnings history
.

Who are some of Recce Pharmaceuticals Ltd (RCE.AX)'s key competitors?

What other stocks do shareholders of Recce Pharmaceuticals Ltd (RCE.AX) own?

Who are Recce Pharmaceuticals Ltd (RCE.AX)'s key executives?

Recce Pharmaceuticals Ltd (RCE.AX)'s management team includes the following people:
  • Mr. James Hamilton-Bray Graham, CEO & MD
  • Ms. Michele Keryn Dilizia, Chief Scientific Director & Exec. Director
  • Dr. Justin Ward, Principal Quality Chemist & Exec. Director
  • Mr. Arthur Kollaras, Principal Engineer & Head of Manufacturing
  • Mr. Justin Reynolds, Chief Financial Officer
  • Prof. Philip Sutton, Member of Clinical Advisory Committee & Head of Helicobacter Pylori Devel. Program
  • Mr. Alistair McKeough BA, LLB, LLM, Company Sec.

What is Recce Pharmaceuticals Ltd (RCE.AX)'s stock symbol?

Recce Pharmaceuticals Ltd (RCE.AX) trades on the ASX under the ticker symbol "RCE."

How big of a company is Recce Pharmaceuticals Ltd (RCE.AX)?

Recce Pharmaceuticals Ltd (RCE.AX) has a market capitalization of $0.00 and generates $1.12 million in revenue each year.

What is Recce Pharmaceuticals Ltd (RCE.AX)'s official website?

The official website for Recce Pharmaceuticals Ltd (RCE.AX) is www.recce.com.au.

How can I contact Recce Pharmaceuticals Ltd (RCE.AX)?

The company can be reached via phone at 61 2 8075 4585.

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.